Home » Topics » BioWorld Science

BioWorld Science
RSS

Roche presents phase II data for olesoxime in patients with SMA

July 13, 2018

Shenzhen Chipscreen Biosciences patents indoleamine 2,3-dioxygenase 1 inhibitors

July 13, 2018

Lilly presents IDH1 and IDH2 mutant inhibitors

July 13, 2018

N-Acetyl-beta-D-glucosaminidase inhibitors identified at Janssen

July 13, 2018

Ono Pharmaceutical initiates phase I study of ONO-5788

July 13, 2018

Audentes Therapeutics presents phase I/II data on AT-132 for XLMTM

July 13, 2018

Positive topline data presented from second pivotal phase III study of ZX-008 in Dravet Syndrome

July 13, 2018

Yale University develops novel SV2A radiotracer for PET imaging of synaptic density

July 13, 2018

Astellas' phase I study of ASP-1948 in advanced solid tumors enrolling patients

July 13, 2018

Beta Therapeutics divulges new heparanase inhibitors

July 13, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...